Contact information of Office of Health Economics
Corrections
All material on this site has been provided by the respective publishers and authors. You can help
correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:respap. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Publications Manager). General contact details of provider: http://edirc.repec.org/data/ohecouk.html .
Content
2020
2019
- 002208 HTA and Payment Mechanisms for New Drugs to Tackle AMR
by Neri, M. & Hampson, G. & Henshall, C. & Towse, A.
- 002187 The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
by Berdud, M. & Wallin-Bernhardsson, N. & Zamora, B. & Lindgren, P. & Towse, A.
- 002184 Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
by Mott, D.J & Shah, K.K & Ramos-Goñi, J.M & Devlin, N.J & Rivero-Arias, O.
- 002154 The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
by Brassel, S. & Rozanova, O. & Towse, A.
- 002150 The Future of Global Health Procurement: Issues around Pricing Transparency
by Berdud, M. & Chalkidou, K. & Dean, E. & Ferraro, J. & Garrison, L. & Nemzoff, C. & Towse, A.
- 002142 Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
by Hernandez-Villafuerte, K. & Zamora, B. & Feng, Y. & Parkin, D. & Devlin, N. & Towse, A.
- 002139 Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
by Cole, A. & Towse, A. & Segal, C.S & Henshall, C. & Pearson, S.D
- 002115 Making Outcome-Based Payment a Reality in the NHS
by Cole, A. & Cubi-Molla, P. & Pollard, J. & Sim, D. & Sullivan, R. & Sussex, J. & Lorgelly, P.
- 002094 Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
by Devlin, N. & Lorgelly, P. & Herdman, M.
2018
- 002044 Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
by Hernandez-Villafuerte, K. & Zamora, B. & Towse, A.
- 002040 R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
by Berdud, M. & Garau, M. & Neri, M. & O'Neill, P. & Sampson, C. & Towse, A.
- 002036 Establishing a Reasonable Price for an Orphan Drug
by Berdud, M. & Drummond, M.F & Towse, A.
- 002030 Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
by Cole, A. & Towse, A. & Lorgelly, P. & Sullivan, R.
- 001998 Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
by Pearson, S. & Dreitlein, B. & Towse, A. & Hampson, G. & Henshall, C.
- 001997 Real World Evidence for Coverage Decisions: Opportunities and Challenges
by Hampson, G. & Towse, A. & Dreitlein, B. & Henshall, C. & Pearson, S.
- 001984 New Methods for Analysing the Distribution of EQ-5D Observations
by Zamora, B. & Parkin, D. & Feng, Y. & Bateman, A. & Herdman, M. & Devlin, N.
2017
- 001885 A New Valuation Method: Directly Eliciting Personal Utility Functions
by Devlin, N. & Shah, K. & Mulhern, B. & Pantiri, K. & van Hout, B.
- 001871 Why Do Immigrants Report Lower Life Satisfaction?
by Yaman, F. & Cubi-Molla, P.
- 001848 'Macro' Evaluation of the NIHR Oxford Biomedical Research Centre
by Hampson, G. & Lichten, C. & Berdud, M. & Pollitt, A. & Mestre-Ferrandiz, J. & Sussex, J. & Towse, A.
- 001830 Age and Utilities: Issues for HTA
by Cubi-Molla, P. & Shah, K.K & Garside, J. & Herdman, M. & Devlin, N.
- 001821 Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets
by Mulhern, B. & Feng, Y. & Shah, K. & van Hout, B. & Janssen, B. & Herdman, M. & Devlin, N.
- 001811 Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
by Marsden, G. & Towse, A. & Pearson, S.D & Dreitlein, B. & Henshall, C.
- 001798 What is the Normative Basis for Selecting the Measure of 'Average' Preferences for Use in Social Choices?
by Devlin, N. & Shah, K.K & Buckingham, K.
2016
- 001777 An Analysis of NICE Technology Appraisal Decisions 'Recommended in Line with Clinical Practice'
by O'Neill, P. & Cole, A. & Duran, A. & Devlin, N.
- 001773 Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
by Garau, M. & Marsden, G. & Devlin, N. & Amedeo Mazzanti, N. & Profico, A.
- 001769 Extrapolation from Progression-Free Survival to Overall Survival in Oncology
by Fischer, A. & Hernandez-Villafuerte, K. & Latimer, N. & Henshall, C.
- 001766 Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public
by Shah, K. & Mulhern, B. & Longworth, L. & Janssen, B.
- 001764 Uncertainty and Risk in HTA Decision Making
by Barnsley, P. & Cubi-Molla, P. & Fischer, A. & Towse, A.
- 001756 The Distribution of the EQ-5D-5L Index in Patient Populations
by Feng, Y. & Devlin, N. & Bateman, A. & Zamora, B. & Parkin, D.
- 001703 A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
by Brockis, E. & Marsden, G. & Cole, A. & Devlin, N.
- 001679 New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data
by Feng, Y. & Devlin, N. & Shah, K. & Mulhern, B. & Van Hout, B.
- 001678 Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England
by Devlin, N. & Shah, K. & Feng, Y. & Mulhern, B. & Van Hout, B.
2015
- 001669 Model of Behaviour within Fuzzy Budget Constraints
by Sussex, J. & Hernandez-Villafuerte, K.
- 001657 Dementia: The R&D Landscape
by Marsden, G. & Mestre-Ferrandiz, J.
- 001632 Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
by Pistollato, M.
- 001582 An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates
by Papadimitropoulos, M. & Elbarazi, I. & Blair, I. & Katsaiti, M.S & Shah, K. & Devlin, N.
2014
- 000530 What Determines the Shape of an EQ-5D Index Distribution?
by Parkin, D. & Devlin, N. & Feng, Y.
- 000519 Exploring the Interdependencies of Research Funders in the UK
by Shah, K. & Sussex, J. & Hernandez-Villafuerte, K. & Garau, M. & Rotolo, D. & Hopkins, M.M & Grassano, N. & Crane, P. & Lang, F. & Hutton, J. & Pateman, C. & Mawer, A. & Farrell, C. & Sharp, T.
- 000517 Opportunity Costs of Implementing NICE Decisions in NHS Wales
by Karlsberg Schaffer, S. & Sussex, J. & Hughes, D. & Devlin, N.
- 000070 Projecting Expenditure on Medicines in the NHS: Second Edition
by O'Neill, P. & Mestre-Ferrandiz, J. & Puig-Peiro, R. & Sussex, J.
2013
- 000125 The Effect of Free Personal Care for the Elderly on Informal Caregiving
by Karlsberg Schaffer, S.
- 000115 Projecting Expenditure on Medicines in the NHS
by O'Neill, P. & Mestre-Ferrandiz, J. & Puig-Peiro, R. & Sussex, J.
- 000114 Multi-Criteria Decision Analysis to Value Orphan Medicines
by Sussex, J. & Rollet, P. & Garau, M. & Schmitt, C. & Kent, A. & Hutchings, A.
- 000108 A Study of the Relationship Between Health and Subjective Well-being in Parkinson's Disease Patients
by Cubi-Molla, P. & de Vries, J. & Devlin, N.
- 000107 The Influence of Cost-effectiveness and Other Factors on NICE Decisions
by Dakin, H. & Devlin, N. & Feng, Y. & Rice, N. & O'Neill, P. & Parkin, D.
- 000078 Searching for Cost-effectiveness Thresholds in NHS Scotland
by Karlsberg Schaffer, S. & Sussex, J. & Devlin, N. & Walker, A.
- 000037 Exploring the link between health and wealth in decision making
by Garau, M. & Shah, K. & Sharma, P. & Towse, A.
2012
- 000165 Assessing the Performance of the EQ-VAS in the NHS PROMs Programme
by Feng, Y. & Parkin, D. & Devlin, N.
- 000162 The Tougher the Better: The Effect of an Increased Performance Threshold on the Performance of General Practitioners
by Feng, Y. & May, A. & Farrar, S. & Sutton, M.
- 000160 Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
by Garau, M. & Towse, A. & Garrison, L. & Housman, L. & Ossa, D.
- 000132 Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment
by Shah, K. & Tsuchiya, A. & Risa Hole, A. & Wailoo, A.
- 000126 Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity
by Shah, K. & Devlin, N.
2011
- 000190 Managing Poorly Performing Clinicians: The Value of Independent Help
by Watson, V. & Sussex, J. & Teeteh, E. & Ryan, M.
- 000188 Incentives for R&D for New Antimicrobial Drugs
by Towse, A. & Sharma, P.
- 000180 Is the Aim of the Health Care System to Maximise QALYs? An Investigation of
by Shah, K. & Praet, C. & Devlin, N. & Sussex, J. & Appleby, J. & Parkin, D.
- 000177 Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
by Sussex, J. & Towse, A. & Devlin, N.
- 000175 The Effect of an Increase in the Rate of Payment on General Practitioner's Intrinsic and Extrinsic Motivation
by Feng, Y. & Farrar, S. & Sutton, M. & May, A.
- 000172 Valuing Health at the End of Life: An Exploratory Preference Elicitation Study
by Shah, K. & Tsuchiya, A. & Wailoo, A.
2010
- 000211 Using QALYs in Cancer: Review of the Methodological Limitations
by Garau, M. & Shah, K. & Mason, A.R & Wang, Q. & Towse, A. & Drummond, M.F
- 000194 A Comparison of Alternative Variants of the Lead and Lag Time TTO
by Devlin, N. & Buckingham, K. & Shah, K. & Tsuchiya, A. & Tilling, C. & Wilkinson, G. & van Hout, B.
Printed from https://ideas.repec.org/s/ohe/respap.html